Transcription of NEW ZEALAND DATA SHEET - Medsafe
{{id}} {{{paragraph}}}
Example: tourism industry
NEW ZEALAND DATA SHEET - Medsafe
Version: pfddepoi11017 Supersedes: pfddepoi11016 Page 1 of 18 NEW ZEALAND DATA SHEET 1. PRODUCT NAME depo - provera 150 mg/mL Injection (depot) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 mL vial contains 150 mg/mL Medroxyprogesterone acetate Each 1 mL disposable syringe contains 150 mg/mL Medroxyprogesterone acetate Excipients with known effects: Sodium Methyl hydroxybenzoate, Propyl hydroxybenzoate, For the full list of excipients, see section 3. PHARMACEUTICAL FORM depo - provera 150 mg/mL Injection (depot) is a white, aqueous, suspension containing medroxyprogesterone acetate (MPA) as the active ingredient. 4. CLINICAL PARTICULARS Therapeutic indications depo - provera is indicated for: ovulation suppression.
Version: pfddepoi11017 Supersedes: pfddepoi11016 . Page 2 of 18 . 4.2 Dose and method of administration . Ovulation suppression . DEPO-PROVERA should be vigorously shaken just before use to ensure that the dose being
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
PROVERA Medroxyprogesterone acetate, PROVERA ® Medroxyprogesterone acetate, Medroxyprogesterone acetate, USPI medroxyprogesterone acetate - Depo, Suspension for injection medroxyprogesterone acetate Single-dose, Approved Prescription Products for Menopausal, Acetate, Public Assessment Report Mutual Recognition, Public Assessment Report Mutual Recognition Procedure